Condition: Alzheimer Disease · Sponsor: Lantheus Biosciences Ltd.
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.
This description comes directly from the study's public registry record.
Audrey Perrotin, PhD · +49 (0)30 461 1246 03 · clinicaltrials@life-mi.com
Aleksandar Jovalekic, PhD · +49 (0)30 461 1246 03 · clinicaltrials@life-mi.com
Always discuss trial participation with your own doctor first.
| Barrow Neurological Institute | Phoenix, Arizona, United States | Recruiting |
| Banner Sun Health Research Institute | Sun City, Arizona, United States | Recruiting |
| UC Los Angeles | Los Angeles, California, United States | Recruiting |
| Esperanza Clinical | Murrieta, California, United States | Recruiting |
| Sutter Health | San Francisco, California, United States | Recruiting |
| Galiz Research | Hialeah, Florida, United States | Recruiting |
| UF College of Medicine - Jacksonville | Jacksonville, Florida, United States | Withdrawn |
| K2 Medical Research | Lady Lake, Florida, United States | Recruiting |
| K2 Medical Research | Maitland, Florida, United States | Recruiting |
| ClinCloud Research | Melbourne, Florida, United States | Recruiting |
| Miami Jewish Health Systems | Miami, Florida, United States | Recruiting |
| The Roskamp Institute | Sarasota, Florida, United States | Terminated |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05641688